Catalog No.
DHD62609
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Target
IL-4RA, IL-4-binding protein, IL-4 receptor subunit alpha, Soluble IL-4R-alpha, IL4-BP, IL4R, IL-4R subunit alpha, IL-4R-alpha, CD124, Interleukin-4 receptor subunit alpha, IL4RA, Soluble IL-4 receptor subunit alpha, sIL4Ralpha/prot
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P24394
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CM310
Clone ID
CM310
Stapokibart (CM310) in patients with uncontrolled seasonal allergic rhinitis (PHECDA): Rationale and design of a multicentre, randomized, double-blind, placebo-controlled study., PMID:40051426
SPECT Imaging of Cardiac Inflammation by Targeting IL4 Receptor-α on Macrophages., PMID:39945732
Stapokibart (CM310) targets IL-4Rα for the treatment of type 2 inflammation., PMID:39262798
Anti-IL-4Rα monoclonal antibody (CM310) in patients with chronic rhinosinusitis with nasal polyps (CROWNS-2): Rationale and design of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study., PMID:39220573
Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial., PMID:39080181
A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis., PMID:39064040
Development and validation of an enzyme-linked immunosorbent assay for the quantification of a recombinant humanized anti-IL-4Rα monoclonal antibody CM310 in serum and its application to pharmacokinetic study in Sprague-Dawley Rats., PMID:39059567
Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial., PMID:39038559
Efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): an investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial., PMID:38356731
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs., PMID:38186219
Blocking Th2 Signaling Pathway Alleviates the Clinical Symptoms and Inflammation in Allergic Conjunctivitis., PMID:37486293
Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial., PMID:37483544
Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial., PMID:37482623
Thermal Evaluation of Multi-Antenna Systems Proposed to Treat Bone Tumors: Finite Element Analysis., PMID:36236709
Recovery material from a new designed surgical face mask: A complementary approach based on mechanical and thermo-chemical recycling., PMID:36191501
For research use only. Not for human or drug use.
